Granulocyte colony-stimulating factor treatment for cyclophosphamide- induced severe neutropenia in Wegener's granulomatosis

Arthritis and Rheumatism

Volumn 42, Issue 8, 1999, Pages 1752-1756

  Hellmich, Bernhard ^b   Schnabel, Armin ^a   Gross, Wolfgang L ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; WEGENER GRANULOMATOSIS;

ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS; TIME FACTORS; WEGENER GRANULOMATOSIS;

EID: 0033503363     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199908)42:8<1752::AID-ANR26>3.0.CO;2-6     Document Type: Article

References (23)

1. Hoffmann GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997;40:2099-104.
2. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
3. Hoffmann GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-99.
4. Guillevin L, Cordier J-F, Lohte F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
5. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32:45-53.
6. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88: 1907-29.
7. Sprikkelman A, de Wolf JTM, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis. Leukemia 1994;8:2031-6.
8. Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol 1994;31:213-5.
9. Johnson MM, Grimwood CR. Leukocyte colony stimulating factors: a review of associated dermatoses and vasculitides. Arch Dermatol 1994;130:77-81.
10. Farhey JD, Herman JH. Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty's syndrome. J Rheumatol 1995;22:1179-81.
11. Viddarson B, Geirsson AJ, Önundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med 1995;98:589-91.
12. Stanworth SJ, Bhavnani M, Chattopahya C, Miller H, Swinson DR. Treatment of Felty's syndrome with hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF). QJM 1998; 91:49-56.
13. Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol 1998;10:45-50.
14. Dreicer R, Schiller JH, Carbone PP, Mueller W, Odenwald E, Souza L, et al. Granulocyte-macrophage colony stimulating factor and vasculitis [letter]. Ann Intern Med 1989;111:91-2.
15. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997;24:2153-7.
16. Wodzinski MA, Hamton KK, Reilly JT. Differential effect of G-CSF and GM-CSF in acquired chronic neutropenia. Br J Haematol 1991;77:249-50.
17. Yang YM, Mankad VN, Manci E. Granulocyte colony-stimulating factor associated leukocytoclastic vasculitis mimicking Henoch-Schoenlein purpura [letter]. Pediatr Hematol Oncol 1993;65:151-2.
18. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
19. Jennette CJ, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
20. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestations and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
21. Yong KL, Linch DC. Differential effects of granulocyte and granulocyte-macrophage colony-stimulating factor (G-and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol 1992;49:251-9.
22. Spiekermann K, Rosler J, Emmendorfer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 1997;11:466-78.
23. Jennette CJ, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998;13 Suppl 1:16-20.